XIAMEN, China & SAN DIEGO--(BUSINESS WIRE)--Amoy Diagnostics Co. Ltd. (ADx) and Illumina, Inc. (NASDAQ: ILMN) today announced a strategic collaboration to accelerate the adoption of precision medicine and targeted therapies in China. Under the collaboration, Amoy will develop and commercialize a series of oncology-related tests based on Illumina's next-generation sequencing (NGS) platforms, including the recently released research use only TruSight Tumor 15 as transferred from Illumina to Amoy. The collaboration reflects the commitment of both companies to provide integrated solutions to meet clinical needs in China.
"Our genetic tests for detection of EGFR, KRAS, NRAS and BRAF mutations and ALK and ROS1 fusions, have led the way for precision medicine adoption in clinical oncology across China. However, as the number of clinically actionable genetic variants in cancer increases, NGS technology is crucial in order for companion diagnostics to keep pace. Illumina is the world-leader in NGS and a natural partner for our company. We intend to combine Amoy’s expertise in molecular diagnostics with Illumina’s superior NGS technology to better serve Chinese cancer patients,” said Dr. Limou Zheng, CEO and President of Amoy Diagnostics.
“We are excited to announce this strategic collaboration with Amoy, which will increase access to our advanced NGS technology in the clinical oncology market in China. Genetic changes are a major cause of cancer development, and the number of clinically actionable genomic variants is growing rapidly. NGS technology, with its ability to generate and analyze large-scale data and its high sensitivity in detecting rare mutations, has shown great value and potential for oncology,” said Dr. Rick Klausner, Senior Vice President and Chief Medical Officer of Illumina. “Working with market leaders such as Amoy is central to Illumina’s strategy to advance personalized cancer diagnostics globally.”
About Amoy Diagnostics
Amoy Diagnostics Co., Ltd. (AmoyDx) is a leading biotech company which pioneered the development and commercialization of cancer diagnostics in China. It is the largest provider of molecular diagnostics products for personalized healthcare in China, as well as a service center for oncology biomarker analysis. AmoyDx has a market-leading portfolio of molecular tests and is the therapy diagnostics partner for several major multinational pharmaceutical companies offering precision therapies for cancer.
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
This release may contain forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in Illumina’s filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.
Dr. Jiemin Luo, +86 5926806830
Rebecca Chambers, 858-255-5243
Jennifer Temple, 858-882-6822